Li Dean Y.'s most recent trade in Merck & Co Inc was a trade of 58,207 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2026 | 58,207 | 58,207 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2026 | 19,885 | 19,885 | - | - | Restricted Stock Unit | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 110.03 per share. | 29 Apr 2026 | 4,722 | 96,757 (0%) | 0% | 110.0 | 519,562 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2026 | 4,722 | 9,444 | - | - | Restricted Stock Unit | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.03 per share. | 29 Apr 2026 | 2,326 | 94,431 (0%) | 0% | 110.0 | 255,930 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Sale of securities on an exchange or to another person at price $ 117.52 per share. | 10 Feb 2026 | 10,235 | 92,035 (0%) | 0% | 117.5 | 1,202,844 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Sale of securities on an exchange or to another person at price $ 118.77 per share. | 04 Feb 2026 | 15,087 | 102,270 (0%) | 0% | 118.8 | 1,791,824 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2026 | 15,087 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.04 per share. | 04 Feb 2026 | 15,087 | 117,357 (0%) | 0% | 56.0 | 845,475 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 107.40 per share. | 26 Jan 2026 | 20,469 | 102,270 (0%) | 0% | 107.4 | 2,198,371 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 64,481 | 64,481 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 14,166 | 14,166 | - | - | Restricted Stock Unit | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 97.94 per share. | 27 Jan 2025 | 32,621 | 79,592 (0%) | 0% | 97.9 | 3,194,901 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 65,625 | 65,625 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Dean Li Y. | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 14,702 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Li Dean Y. | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.07 per share. | 09 Feb 2024 | 14,702 | 60,944 (0%) | 0% | 62.1 | 912,553 | Common Stock |
| Merck & Company | Y. Dean Li | Executive VP & President, MRL | Sale of securities on an exchange or to another person at price $ 125.50 per share. | 09 Feb 2024 | 14,702 | 46,242 (0%) | 0% | 125.5 | 1,845,083 | Common Stock |
| Merck & Company | Y. Dean Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 119.43 per share. | 22 Jan 2024 | 25,760 | 46,242 (0%) | 0% | 119.4 | 3,076,517 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 77,455 | 77,455 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.47 per share. | 01 May 2023 | 1,062 | 20,995 (0%) | 0% | 115.5 | 122,629 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 1,062 | 0 | - | - | Restricted Stock Unit | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.47 per share. | 01 May 2023 | 524 | 20,471 (0%) | 0% | 115.5 | 60,506 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 109.88 per share. | 23 Jan 2023 | 3,275 | 19,933 (0%) | 0% | 109.9 | 359,857 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2022 | 75,728 | 75,728 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 773 | 0 | - | - | Restricted Stock Unit | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.65 per share. | 03 May 2022 | 773 | 16,838 (0%) | 0% | 87.6 | 67,753 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.65 per share. | 03 May 2022 | 381 | 16,457 (0%) | 0% | 87.7 | 33,395 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2022 | 1,061 | 1,062 | - | - | Restricted Stock Unit | |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.69 per share. | 01 May 2022 | 1,061 | 16,588 (0%) | 0% | 88.7 | 94,100 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.69 per share. | 01 May 2022 | 523 | 16,065 (0%) | 0% | 88.7 | 46,385 | Common Stock |
| Merck & Company | Dean Y. Li | Executive VP & President, MRL | Grant, award, or other acquisition of securities at price $ 73.51 per share. | 24 Feb 2022 | 3,023 | 15,462 (0%) | 0% | 73.5 | 222,221 | Common Stock |